Effects of H.Pylori Eradication on Microbiome
Launched by UNIVERSITY OF LATVIA · Jul 26, 2017
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The current international guidelines and expert working groups are encouraging "search-and-treat" strategy for H.pylori to prevent gastric cancer1, 2. The highest yield of this approach is expected in countries with high incidence of gastric cancer and high prevalence of H.pylori infection. This approach will be further supported by the Maastricht V European guidelines (manuscript in preparation). The rationale for this approach is that 1-2% of the infected individuals are developing gastric cancer; the International Agency for Research on Cancer has classified H.pylori infection as Class I...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals with established H.pylori infection
- • Individuals in whom H.pylori eradication therapy is indicated according to the international or national recommendations
- • Individuals who agree to undergo H.pylori eradication therapy
- Exclusion Criteria:
- • Severely sick patients
- • Individuals in whom H.pylori eradication therapy is contra-indicated due to any reasons
- • Individuals unable or unwilling to provide a sample for microbiome testing
About University Of Latvia
The University of Latvia is a leading academic institution dedicated to advancing knowledge and research in various fields, including medicine and health sciences. As a clinical trial sponsor, the University leverages its extensive expertise and resources to facilitate innovative research initiatives aimed at improving patient outcomes and contributing to the scientific community. The institution prioritizes ethical standards and regulatory compliance, ensuring that all trials are conducted with the utmost integrity and a commitment to participant safety. Through collaboration with healthcare professionals and researchers, the University of Latvia fosters an environment that encourages groundbreaking discoveries and enhances the quality of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Riga, , Latvia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials